



Financial Results (Consolidated) for Nine Months Ended December 31, 2023

FUJIFILM Holdings Corporation

Teiichi Goto

President and Chief Executive Officer

Projected date of Quarterly Report: February 14, 2024

Projected date of the beginning of cash dividends: —

Reference materials regarding operating results of the current quarter to be prepared: Yes

Meeting to explain operating results of the current quarter to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

February 8, 2024

URL: <https://holdings.fujifilm.com/en>

1. Results of the Nine Months Ended December 31, 2023 (From April 1, 2023 to December 31, 2023)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

#: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
	Yen	%	Yen	%	Yen	%	Yen	%
Nine months ended Dec. 31, 2023	2,155,411	2.9	204,927	1.1	229,664	12.1	173,760	13.0
Nine months ended Dec. 31, 2022	2,094,260	12.5	202,637	8.7	204,787	(1.2)	153,735	(2.1)

Note: Comprehensive income

Nine months ended December 31, 2023 ¥288,860 million (32.9%) Nine months ended December 31, 2022 ¥217,351 million (7.6%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)
	Yen	Yen
Nine months ended Dec. 31, 2023	433.08	432.56
Nine months ended Dec. 31, 2022	383.43	382.85

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets
	Yen	Yen	Yen	%
As of Dec. 31, 2023	4,549,044	2,974,768	2,971,403	65.3
As of March 31, 2023	4,134,311	2,787,860	2,763,145	66.8

2. Cash Dividends

	Cash dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2023	-	60.00	-	70.00	130.00
Year ending March 31, 2024	-	70.00	-	-	-
Year ending March 31, 2024 (Forecast)	-	-	-	80.00	150.00

Note: Changes in dividends forecast during the quarter under review: None

Note: Details of year-end dividends for the fiscal year ending March 31, 2024

Ordinary dividend ¥ 70.00 90th anniversary commemorative dividend ¥ 10.00

3. Forecast for the Fiscal Year Ending March 31, 2024 (From April 1, 2023 to March 31, 2024)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

#: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
	Yen	%	Yen	%	Yen	%	Yen	%	Yen
For the Year ending March 31, 2024	2,950,000	3.2	290,000	6.2	295,000	4.5	225,000	2.5	560.61

Note: Changes in forecast which was recently announced: None

Note: Net income attributable to FUJIFILM Holdings per share is calculated using the number of shares issued as of December 31, 2023 excluding treasury shares for the average number of shares for the relevant period.

Notes

(1) Changes in status of material subsidiaries during this quarter
(Company newly consolidated or removed from consolidation): None

(2) Adoption of simplified method of accounting or specific accounting treatments: None

(3) Changes in accounting principles

1. Changes in accounting policies accompanied by revisions of accounting standards: Yes
2. Changes in accounting policies other than 1. above: None

(4) Number of shares outstanding

1. Issued (including treasury stock):
2. Treasury stock:
3. Average number of shares:

As of Dec. 31, 2023	414,625,728	As of March 31, 2023	414,625,728
As of Dec. 31, 2023	13,278,189	As of March 31, 2023	13,528,181
Nine months ended Dec. 31, 2023	400,939,197	Nine months ended Dec. 31, 2022	400,752,991

This report is not reviewed.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have an intention of guaranteeing the realization of the forecasts. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecasts and warnings for users of the forecasts are mentioned in the page 5, (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results in 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER.

[INDEX]

1.	QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER	P.2
	(1) Explanation on Consolidated Operating Results	P.2
	(2) Explanation on the Consolidated Financial Position	P.4
	(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results	P.5
2.	MATTERS RELATING TO SUMMARY (OTHER) INFORMATION	P.5
	(1) Changes in Status of Material Subsidiaries during This Quarter	P.5
	(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments	P.5
	(3) Changes in Accounting Principles	P.6
3.	OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION	P.6
4.	CONSOLIDATED FINANCIAL STATEMENTS	P.7
	(1) Consolidated Balance Sheets	P.7
	(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	P.9
	(Consolidated Statements of Income)	P.9
	Nine months ended December 31	P.9
	Three months ended December 31	P.10
	(Consolidated Statements of Comprehensive Income)	P.11
	Nine months ended December 31	P.11
	Three months ended December 31	P.11
	(3) Consolidated Statements of Cash Flows	P.12
	(4) Notes to Consolidated Financial Statements	P.13
	(Notes Relating to the Going Concern Assumption)	P.13
	(Segment Information)	P.13
	1) Nine months ended December 31	P.13
	2) Three months ended December 31	P.14
	(Notes on Significant Changes to FUJIFILM Holdings Shareholders' Equity)	P.14
	(Significant Subsequent Events)	P.15

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER

(1) Explanation on Consolidated Operating Results

Amount Unit: Billions of yen

	Nine months ended December 31, 2023		Nine months ended December 31, 2022		Change (Amount)	Change (%)
Domestic revenue	34.9%	751.2	34.5%	722.8	28.4	3.9%
Overseas revenue	65.1%	1,404.2	65.5%	1,371.5	32.7	2.4%
Revenue	100.0%	2,155.4	100.0%	2,094.3	61.1	2.9%
Operating income	9.5%	204.9	9.7%	202.6	2.3	1.1%
Income before income taxes	10.7%	229.7	9.8%	204.8	24.9	12.1%
Net income attributable to FUJIFILM Holdings	8.1%	173.8	7.3%	153.7	20.1	13.0%
Exchange rates (Yen / US\$)		¥144		¥137	¥7	
Exchange rates (Yen / Euro)		¥156		¥141	¥15	

In the nine months ended December 31, 2023, the Fujifilm Group recorded ¥2,155.4 billion in consolidated revenue (up 2.9% year-over-year), reflecting sales increases mainly in the medical systems and imaging businesses.

Operating income increased to ¥204.9 billion (up 1.1% year-over-year). Consolidated income before income taxes amounted to ¥229.7 billion (up 12.1% year-over-year), reflecting such factors as an increase in valuation gains on marketable and investment securities, and consolidated net income attributable to FUJIFILM Holdings amounted to ¥173.8 billion (up 13.0% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during the nine months were ¥144 and ¥156, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Nine months ended December 31, 2023	Nine months ended December 31, 2022	Change (Amount)	Change (%)
Healthcare	690.7	641.8	48.9	7.6%
Materials	494.7	514.7	(20.0)	(3.9%)
Business Innovation	601.4	614.1	(12.7)	(2.1%)
Imaging	368.6	323.7	44.9	13.8%
Consolidated Total	2,155.4	2,094.3	61.1	2.9%

Operating Income by Operating Segment

Amount Unit: Billions of yen

Segment	Nine months ended December 31, 2023	Nine months ended December 31, 2022	Change (Amount)	Change (%)
Healthcare	60.3	62.2	(1.9)	(3.2%)
Materials	31.4	57.9	(26.5)	(45.8%)
Business Innovation	50.4	47.8	2.6	5.5%
Imaging	88.9	62.7	26.2	41.7%
Corporate Expenses and Eliminations	(26.1)	(28.0)	1.9	—
Consolidated Total	204.9	202.6	2.3	1.1%

*The non-destructive inspection equipment / materials, which had been included in the industrial products business, has been changed from the Materials segment to the Healthcare segment. Figures for the first nine months of the previous fiscal year are also based on the segment classification after the above change.

Healthcare

In the Healthcare segment, consolidated revenue amounted to ¥690.7 billion (up 7.6% year-over-year).

Operating income amounted to ¥60.3 billion (down 3.2% year-over-year).

In the medical systems business, revenue increased mainly due to steady sales of endoscopes and CT/MRI systems. In the X-ray imaging diagnostics field, revenue increased due to growing sales of the mobile X-ray equipment *FDR Go PLUS* and other digital radiography products in the U.S., as well as growing sales of the digital mammography system *AMULET Innovality* mainly in Europe and South/Central America. In the medical IT field, revenue increased due to strong sales of systems and services, in particular the Picture Archiving and Communication System (PACS) *SYNAPSE* and the 3D image analysis system *SYNAPSE VINCENT*, mainly in the U.S., Europe and other overseas markets. In the ultrasound diagnostics field, despite higher sales of the new *DeepInsight series* of stationary ultrasound diagnostic systems mainly in Japan, revenue declined due to weak sales in China. In the endoscopes field, revenue increased due to growing sales of products such as the *7000 System*, which installs image emphasis features including LCI (Linked Color Imaging) that support endoscope observations by emphasizing slight differences in color of mucous membrane, mainly in Japan, Europe and China. In the In-Vitro Diagnostics (IVD) field, revenue remained flat year-over-year as growing sales of *FUJI DRI-CHEM* (blood biochemical test) equipment and slides offset the lower demand for COVID-19-related reagents. In the CT/MRI field, revenue increased due to higher sales in South/Central America, the Middle East and India.

In the bio CDMO business, revenue increased mainly due to productivity improvements at the Denmark site as well as steady progress in contract manufacturing of antibody drugs. In November 2023, we announced a long-term contract manufacturing agreement with Janssen Supply Group, LLC, a Johnson & Johnson company, for whom we will manufacture biopharmaceuticals at our large-scale manufacturing facility in North Carolina, U.S., which is expected to be fully operational in 2025. In December 2023, we announced the investment aimed at expanding manufacturing capabilities at our sites in Wisconsin and California, U.S., in an effort to meet the CDMO needs for cell therapies, where high market growth is expected over the medium to long term. In the high-growth biopharmaceutical market, we will further accelerate business growth by meeting diverse customer needs ranging from small-scale to large-scale production and from active pharmaceutical ingredients to contract formulation and packaging, in addition to offering contract development of production processes.

In the life sciences business, revenue increased due to higher sales of cell culture media and steady sales of cells to be used in drug discovery support. The cell culture media market has been growing in tandem with higher demand for antibody drugs. We will provide strong support for R&D and manufacturing of biopharmaceuticals through our global manufacturing structure based in the U.S., Europe and Japan.

In the pharmaceutical business, revenue increased thanks to contributions from contract manufacturing of COVID-19 vaccine candidates in Japan and an upturn in demand for antibacterial agents.

In the consumer healthcare business, overall revenue declined due to lower sales of supplements, although sales increased for new cosmetic products, namely *ASTALIFT ADVANCED LOTION* and *ASTALIFT ADVANCED CREAM*.

Materials

In the Materials segment, consolidated revenue amounted to ¥494.7 billion (down 3.9% year-over-year).

Operating income amounted to ¥31.4 billion (down 45.8% year-over-year).

In the electronic materials business, despite the stagnant semiconductor market conditions, revenue was in line with the same period a year earlier thanks to the semiconductor process chemicals business acquired from Entegris, Inc. of the U.S. in October 2023. We will further expand the new business by strengthening our ability to meet customer needs based on a broader product lineup. In anticipation of future semiconductor market expansion, we announced in April 2023 the expansion of production capacity at our semiconductor materials manufacturing site in Europe, in May 2023 the establishment of a new state-of-the-art semiconductor materials manufacturing site in Taiwan, and in January 2024 the installation of a cutting-edge semiconductor materials production facility at the Kumamoto site. We will continue to make aggressive capital investments to ensure stable production of high-quality materials and build a robust global manufacturing structure.

In the display materials business, revenue increased compared to the same period a year earlier when the entire supply chain was in a production adjustment phase.

In the industrial products business, revenue declined mainly due to sluggish demand for data archiving tapes, as

major IT companies cut back on investment in data center construction, and lower sales of *EXCLEAR* sensor film for touch panels, which was affected by weak demand for business PCs.

In the fine chemicals business, revenue declined due to lower sales of chemical products, which were hit by sluggish demand for polymerization materials in Europe.

In the graphic communication business, revenue in the printing plates field declined due to lower demand for printed materials mainly in Europe and the U.S. In the digital printing field, efforts continue to expand the business further, including the launch of the medium- to high-speed production color printers *Revoria Press EC1100* and *Revoria Press SC180/SC170*, as well as the expansion of sales activities for our print-on-demand digital printers in the U.S., U.K., France and Canada, which started in April 2023. In the inkjet field, revenue decreased due to lower shipments of inkjet printheads for the ceramic market, affected by stagnant real estate market conditions in China and sluggish demand in Europe stemming from monetary tightening.

Business Innovation

In the Business Innovation segment, consolidated revenue amounted to ¥601.4 billion (down 2.1% year-over-year).

Operating income amounted to ¥50.4 billion (up 5.5% year-over-year).

In the office solutions business, revenue declined, mainly hit by lower exports to Europe and the U.S., despite expansion of new OEMs, the effect of worldwide sales price revisions and other favorable factors.

In the business solutions business, revenue rose mainly due to an increase in sales to municipalities in Japan and higher sales of digital transformation (DX)-related solutions. In November 2023, as the second phase of our solution / service to realize CHX (Customer Happy Experience) through customers' DX activities, we started offering the *FUJIFILM IWpro*, a cloud service that supports business process transformation and accelerates DX through maximum use of customers' current systems, in Japan and Asia-Pacific region. In addition to expanding our portfolio of business and operations solutions, we will accelerate business growth by increasing core DX solutions and expanding BPO (Business Process Outsourcing) services that facilitate business innovation and ITO (Information Technology Outsourcing) services that support construction and operation of the IT infrastructure environment.

Imaging

In the Imaging segment, consolidated revenue amounted to ¥368.6 billion (up 13.8% year-over-year).

Operating income amounted to ¥88.9 billion (up 41.7% year-over-year).

In the consumer imaging business, steady sales of the *INSTAX* instant photo systems drove revenue higher. In addition to the existing product lineup, sales of *INSTAX mini Evo*, *INSTAX Pal*, a palm-sized camera launched in October 2023, and other high value-added products fared well. We will continue to expand the world of the *INSTAX* instant photo system that allows people to enjoy on-the-spot photo printing.

In the professional imaging business, revenue increased as sales of digital cameras remained strong. In addition to brisk sales of *X-H2*, *X-H2S* and *X-T5* launched in the previous fiscal year, sales of *X-S20* launched in June 2023 and *GFX100 II* launched in September 2023 were also strong. In October 2023, we started offering the *Tunnel inspection DX solution* that improves tunnel inspection efficiency by using the latest optical technology, image processing technology and AI. We remain committed to contributing to the resolution of social issues by promoting digital transformation in the infrastructure sector through our products and services based on cutting-edge and proprietary technologies.

(2) Explanation on the Consolidated Financial Position

At the end of the nine months ended December 31, 2023, total assets increased by ¥414.7 billion compared with the end of the previous fiscal year (March 31, 2023) to ¥4,549.0 billion, mainly due to increases in property, plant and equipment. Total liabilities increased by ¥227.8 billion to ¥1,574.2 billion. FUJIFILM Holdings shareholders' equity increased by ¥208.3 billion to ¥2,971.4 billion. As a result, the current ratio decreased by 39.7 percentage points to 143.5%, the debt-equity ratio increased by 4.3 percentage points to 53.0%, and the equity ratio decreased by 1.5 percentage points to 65.3% compared with the end of the previous fiscal year. The Company is maintaining a stable level of asset liquidity and a sound capital structure.

(Cash Flows)

Amount Unit: Billions of yen

	Nine months ended December 31, 2023	Nine months ended December 31, 2022	Change
Net cash provided by operating activities	242.0	63.2	178.8
Net cash used in investing activities	(391.3)	(226.0)	(165.3)
Net cash used in financing activities	107.2	(21.3)	128.5

During the nine months ended December 31, 2023, net cash provided by operating activities totaled ¥242.0 billion, due to a decrease in notes and accounts receivables and other factors. Net cash used in investing activities amounted to ¥391.3 billion due to the purchase of property, plants and equipment, business acquisitions and other factors. As a result, free cash flow, or the sum of cash flow from operating and investing activities, was negative ¥149.3 billion. Net cash used in financing activities amounted to ¥107.2 billion, due to the issuance of commercial paper and other factors. As a result, cash and cash equivalents at the end of the quarter under review amounted to ¥242.9 billion, down ¥25.7 billion from the end of the previous fiscal year (March 31, 2023).

(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results

(Consolidated financial forecast for the fiscal year ending March 31, 2024)

Amount Unit: Billions of yen

	Year ending March 31, 2024 (Forecast)	Year ended March 31, 2023 (Results)	Change (% / Amount)
Revenue	2,950.0	2,859.0	3.2%
Operating income	290.0	273.1	6.2%
Income before income taxes	295.0	282.2	4.5%
Net income attributable to FUJIFILM Holdings	225.0	219.4	2.5%
ROE (%)	8.0	8.3	(0.3 points)
ROIC (%)	5.9	6.1	(0.2 points)
Exchange rates (Yen / US\$)	¥144	¥136	¥8
Exchange rates (Yen / Euro)	¥155	¥141	¥14

Regarding the consolidated performance forecast for the fiscal year ending March 31, 2024, the Company projects ¥2,950.0 billion in consolidated revenue (up 3.2% year-over-year), ¥290.0 billion in operating income (up 6.2% year-over-year), ¥295.0 billion in income before income taxes (up 4.5% year-over-year) and ¥225.0 billion in net income attributable to FUJIFILM Holdings (up 2.5% year-over-year), based on such factors as business growth centered on healthcare and advanced materials and profitability improvement in all businesses.

The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year ending March 31, 2024 are ¥144 and ¥155, respectively.

2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION

(1) Changes in Status of Material Subsidiaries during This Quarter (Company Newly Consolidated or Removed from Consolidation):

None

(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments:

None

(3) Changes in Accounting Principles:

In June 2016, the FASB issued Accounting Standards Update 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments.” Accounting Standards Update 2016-13 requires losses to be recognized for financial assets based on the expected credit loss model rather than the current incurred loss model. Under the expected credit loss model, an allowance is recognized for estimated uncollectible contractual cash flows. The standard is effective for fiscal years (including interim periods) beginning on or after December 15, 2022, with early adoption permitted. The Company adopted Accounting Standards Update 2016-13 from the fiscal year beginning on April 1, 2023 with a cumulative effect adjustment made at the beginning of the first fiscal year of adoption. The adoption of Accounting Standards Update 2016-13 does not have a material impact on the Company's results of operations and financial position.

3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION:

None.

4. CONSOLIDATED FINANCIAL STATEMENTS

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of December 31, 2023	As of March 31, 2023	Change
ASSETS			
Current assets:			
Cash and cash equivalents	242,939	268,608	(25,669)
Notes and accounts receivable:			
Trade and finance	602,659	608,645	(5,986)
Lease receivable	39,210	40,038	(828)
Affiliated companies	2,164	2,561	(397)
Allowance for doubtful receivables	-	(18,193)	18,193
Allowance for credit losses	(19,015)	-	(19,015)
	625,018	633,051	(8,033)
Inventories	599,251	567,302	31,949
Prepaid expenses and other	156,471	162,146	(5,675)
Total current assets	1,623,679	1,631,107	(7,428)
Investments and long-term receivables:			
Investments in and advances to affiliated companies	40,341	42,921	(2,580)
Investment securities	75,040	70,745	4,295
Long-term lease receivables	53,849	55,487	(1,638)
Other long-term receivables	28,843	22,103	6,740
Allowance for doubtful receivables	-	(2,351)	2,351
Allowance for credit losses	(2,109)	-	(2,109)
Total investments and long-term receivables	195,964	188,905	7,059
Property, plant and equipment:			
Land	113,024	105,923	7,101
Buildings	799,390	770,926	28,464
Machinery and equipment and other	1,561,526	1,505,008	56,518
Construction in progress	587,581	345,253	242,328
	3,061,521	2,727,110	334,411
Less accumulated depreciation	(1,805,075)	(1,750,999)	(54,076)
Total property, plant and equipment	1,256,446	976,111	280,335
Other assets:			
Operating lease right-of-use assets	92,733	82,276	10,457
Goodwill, net	954,285	858,311	95,974
Other intangible assets, net	141,223	144,258	(3,035)
Other	284,714	253,343	31,371
Total other assets	1,472,955	1,338,188	134,767
Total assets	4,549,044	4,134,311	414,733

Amount Unit: Millions of yen

	As of December 31, 2023	As of March 31, 2023	Change
LIABILITIES			
Current liabilities:			
Short-term debt	373,597	106,093	267,504
Notes and accounts payable:			
Trade	241,179	246,093	(4,914)
Construction	83,383	72,713	10,670
Affiliated companies	1,308	1,603	(295)
	325,870	320,409	5,461
Accrued income taxes	41,303	39,214	2,089
Accrued liabilities	226,962	234,809	(7,847)
Short-term operating lease liabilities	33,351	31,031	2,320
Other current liabilities	130,489	158,766	(28,277)
Total current liabilities	1,131,572	890,322	241,250
Long-term liabilities:			
Long-term debt	235,705	270,060	(34,355)
Accrued pension and severance costs	20,615	21,909	(1,294)
Long-term operating lease liabilities	63,734	55,400	8,334
Other long-term liabilities	122,650	108,760	13,890
Total long-term liabilities	442,704	456,129	(13,425)
Total liabilities	1,574,276	1,346,451	227,825
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 800,000,000 shares			
Issued: 414,625,728 shares			
Retained earnings	2,703,480	2,616,191	87,289
Accumulated other comprehensive income	283,741	163,820	119,921
Treasury stock, at cost	(56,181)	(57,229)	1,048
Total FUJIFILM Holdings shareholders' equity	2,971,403	2,763,145	208,258
Noncontrolling interests	3,365	24,715	(21,350)
Total equity	2,974,768	2,787,860	186,908
Total liabilities and equity	4,549,044	4,134,311	414,733

Note: Details of accumulated other comprehensive income (loss)

	As of December 31, 2023	As of March 31, 2023	Change
Foreign currency translation adjustments	353,562	232,893	120,669
Pension liability adjustments	(69,810)	(69,193)	(617)
Unrealized gains (losses) on derivatives	(11)	120	(131)

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

Nine months ended December 31

Amount Unit: Millions of yen

	Nine months ended December 31, 2023 From April 1, 2023 To December 31, 2023		Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Change	
	Amount	%	Amount	%	Amount	%
Revenue	100.0	2,155,411	100.0	2,094,260	61,151	2.9
Cost of sales	59.4	1,280,654	59.8	1,252,475	28,179	2.2
Gross profit	40.6	874,757	40.2	841,785	32,972	3.9
Operating expenses:						
Selling, general and administrative	25.6	552,115	25.0	524,210	27,905	5.3
Research and development	5.5	117,715	5.5	114,938	2,777	2.4
Operating income	31.1	669,830	30.5	639,148	30,682	4.8
Operating income	9.5	204,927	9.7	202,637	2,290	1.1
Other income (expenses):						
Interest and dividend income		9,311		5,248	4,063	
Interest expense		(6,061)		(2,555)	(3,506)	
Foreign exchange gains (losses), net		(1,522)		(3,287)	1,765	
Gains (losses) on equity securities, net		15,730		(3,432)	19,162	
Other, net		7,279		6,176	1,103	
Income before income taxes	1.2	24,737	0.1	2,150	22,587	-
Income before income taxes	10.7	229,664	9.8	204,787	24,877	12.1
Income taxes	2.7	58,910	2.6	53,409	5,501	10.3
Equity in net earnings (losses) of affiliated companies	0.0	2,231	0.2	3,565	(1,334)	(37.4)
Net income	8.0	172,985	7.4	154,943	18,042	11.6
Less: Net (income) loss attributable to the noncontrolling interests	0.1	775	(0.1)	(1,208)	1,983	-
Net income attributable to FUJIFILM Holdings	8.1	173,760	7.3	153,735	20,025	13.0

Three months ended December 31

Amount Unit: Millions of yen

	Three months ended December 31, 2023 From October 1, 2023 To December 31, 2023		Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022		Change	
					Amount	%
	%		%			
Revenue	100.0	766,941	100.0	744,329	22,612	3.0
Cost of sales	58.7	450,571	59.6	443,258	7,313	1.6
Gross profit	41.3	316,370	40.4	301,071	15,299	5.1
Operating expenses:						
Selling, general and administrative	25.8	197,695	24.2	180,813	16,882	9.3
Research and development	5.1	39,294	5.2	38,431	863	2.2
Operating income	30.9	236,989	29.4	219,244	17,745	8.1
Operating income	10.4	79,381	11.0	81,827	(2,446)	(3.0)
Other income (expenses):						
Interest and dividend income		3,341		2,241	1,100	
Interest expense		(2,199)		(752)	(1,447)	
Foreign exchange gains (losses), net		(6,173)		(7,618)	1,445	
Gains (losses) on equity securities, net		892		(2,922)	3,814	
Other, net		2,348		2,477	(129)	
Income before income taxes	(0.3)	(1,791)	(0.9)	(6,574)	4,783	-
Income before income taxes	10.1	77,590	10.1	75,253	2,337	3.1
Income taxes	2.4	18,042	2.5	18,425	(383)	(2.1)
Equity in net earnings of affiliated companies	0.2	777	0.2	1,480	(703)	(47.5)
Net income	7.9	60,325	7.8	58,308	2,017	3.5
Less: Net (income) loss attributable to the noncontrolling interests	(0.1)	(125)	0.1	264	(389)	-
Net income attributable to FUJIFILM Holdings	7.8	60,200	7.9	58,572	1,628	2.8

(Consolidated Statements of Comprehensive Income)**Nine months ended December 31**

Amount Unit: Millions of yen

	Nine months ended December 31, 2023 From April 1, 2023 To December 31, 2023	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022	Change
Net income	172,985	154,943	18,042
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	—	(182)	182
Foreign currency translation adjustments	116,130	60,858	55,272
Pension liability adjustments	(124)	1,554	(1,678)
Unrealized gains (losses) on derivatives	(131)	178	(309)
Total	115,875	62,408	53,467
Comprehensive income	288,860	217,351	71,509
Less: Comprehensive income attributable to noncontrolling interests	4,821	(2,131)	6,952
Comprehensive income (loss) attributable to FUJIFILM Holdings	293,681	215,220	78,461

Three months ended December 31

Amount Unit: Millions of yen

	Three months ended December 31, 2023 From October 1, 2023 To December 31, 2023	Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022	Change
Net income	60,325	58,308	2,017
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	—	(258)	258
Foreign currency translation adjustments	(63,566)	(90,034)	26,468
Pension liability adjustments	(390)	497	(887)
Unrealized gains (losses) on derivatives	(21)	143	(164)
Total	(63,977)	(89,652)	25,675
Comprehensive income	(3,652)	(31,344)	27,692
Less: Comprehensive income attributable to noncontrolling interests	(39)	1,810	(1,849)
Comprehensive income (loss) attributable to FUJIFILM Holdings	(3,691)	(29,534)	25,843

(3) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Nine months ended December 31, 2023 From April 1, 2023 To December 31, 2023	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022	Change
Operating activities			
Net income	172,985	154,943	18,042
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	110,149	106,734	3,415
(Gains) losses on equity securities, net	(15,730)	3,432	(19,162)
Equity in net (gains) losses of affiliated companies, net of dividends received	(1,696)	(2,960)	1,264
Changes in operating assets and liabilities:			
Notes and accounts receivable	33,367	(46,773)	80,140
Inventories	(6,551)	(108,312)	101,761
Notes and accounts payable - trade	(13,436)	9,507	(22,943)
Changes in other current assets	(4,070)	(16,576)	12,506
Accrued income taxes and other liabilities	(19,737)	(29,443)	9,706
Other	(13,285)	(7,322)	(5,963)
Subtotal	69,011	(91,713)	160,724
Net cash provided by operating activities	241,996	63,230	178,766
Investing activities			
Purchases of property, plant and equipment	(298,954)	(191,004)	(107,950)
Purchases of software	(32,982)	(35,638)	2,656
Proceeds from sales and maturities of marketable and investment securities	12,503	28,006	(15,503)
Purchases of marketable and investment securities	(723)	(3,316)	2,593
(Increase) decrease in time deposits, net	1,637	(3,855)	5,492
Increase in investments in and advances to affiliated companies	(253)	(512)	259
Acquisitions of businesses, net of cash acquired	(103,921)	(15,428)	(88,493)
Proceeds from sale of businesses, net of cash and cash equivalents disposed of	12,356	-	12,356
Other	19,010	(4,232)	23,242
Net cash used in investing activities	(391,327)	(225,979)	(165,348)
Financing activities			
Proceeds from long-term debt	-	120,164	(120,164)
Repayments of long-term debt	(67,563)	(91,684)	24,121
Increase (decrease) in short-term debt with maturities of three months or less, net	299,062	(639)	299,701
Cash dividends paid to shareholders	(56,170)	(46,109)	(10,061)
Subsidiaries' cash dividends paid to noncontrolling interests	(12,575)	(372)	(12,203)
Net purchases of stock for treasury	(20)	(18)	(2)
Capital transactions with noncontrolling interests	(57,895)	218	(58,113)
Other	2,399	(2,858)	5,257
Net cash provided by (used in) financing activities	107,238	(21,298)	128,536
Effect of exchange rate changes on cash and cash equivalents	16,424	15,558	866
Net decrease in cash and cash equivalents	(25,669)	(168,489)	142,820
Cash and cash equivalents at beginning of period	268,608	486,328	(217,720)
Cash and cash equivalents at end of period	242,939	317,839	(74,900)

(4) Notes to Consolidated Financial Statements

Note Relating to the Going Concern Assumption

N/A

Segment Information

1. Nine months ended December 31

(A) Operating Segment Information

a. Revenue

Amount Unit: Millions of yen

	Nine months ended December 31, 2023 From April 1, 2023 To December 31, 2023		Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Change	
	%		%		Amount	%
Revenue:						
Healthcare:						
External customers	32.0	690,712	30.6	641,776	48,936	7.6
Intersegment		20		48	(28)	-
Total		690,732		641,824	48,908	7.6
Materials:						
External customers	23.0	494,776	24.6	514,656	(19,880)	(3.9)
Intersegment		915		913	2	-
Total		495,691		515,569	(19,878)	(3.9)
Business Innovation:						
External customers	27.9	601,350	29.3	614,079	(12,729)	(2.1)
Intersegment		4,931		6,768	(1,837)	-
Total		606,281		620,847	(14,566)	(2.3)
Imaging:						
External customers	17.1	368,573	15.5	323,749	44,824	13.8
Intersegment		1,069		1,967	(898)	-
Total		369,642		325,716	43,926	13.5
Eliminations		(6,935)		(9,696)	2,761	-
Consolidated total	100.0	2,155,411	100.0	2,094,260	61,151	2.9

b. Operating income

Amount Unit: Millions of yen

	Nine months ended December 31, 2023 From April 1, 2023 To December 31, 2023		Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Change	
	%		%		Amount	%
Operating Income:						
Healthcare	8.7	60,267	9.7	62,247	(1,980)	(3.2)
Materials	6.3	31,380	11.2	57,899	(26,519)	(45.8)
Business Innovation	8.3	50,406	7.7	47,793	2,613	5.5
Imaging	24.0	88,878	19.3	62,732	26,146	41.7
Total		230,931		230,671	260	0.1
Corporate expenses and eliminations		(26,004)		(28,034)	2,030	-
Consolidated total	9.5	204,927	9.7	202,637	2,290	1.1

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Materials:	Electronic materials, display materials, industrial equipment, fine chemicals, equipment and materials for graphic communication, inks and industrial inkjet printheads, etc.
Business Innovation:	Digital MFPs, solutions and services, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

c. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Nine months ended December 31, 2023 From April 1, 2023 To December 31, 2023		Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Change	
					Amount	%
Revenue:	%		%			
Domestic	34.9	751,230	34.5	722,759	28,471	3.9
Overseas:						
The Americas	22.1	477,040	23.3	488,110	(11,070)	(2.3)
Europe	15.4	331,942	15.2	318,014	13,928	4.4
Asia and others	27.6	595,199	27.0	565,377	29,822	5.3
Subtotal	65.1	1,404,181	65.5	1,371,501	32,680	2.4
Consolidated total	100.0	2,155,411	100.0	2,094,260	61,151	2.9

Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer's location.

2. Three months ended December 31

(A) Revenue by Operating Segment

Amount Unit: Millions of yen

	Three months ended December 31, 2023 From October 1, 2023 To December 31, 2023		Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022		Change	
					Amount	%
Revenue:	%		%			
Healthcare	31.6	242,494	29.6	220,530	21,964	10.0
Materials	22.8	175,160	22.5	167,799	7,361	4.4
Business Innovation	26.1	199,872	29.0	215,656	(15,784)	(7.3)
Imaging	19.5	149,415	18.9	140,344	9,071	6.5
Consolidated total	100.0	766,941	100.0	744,329	22,612	3.0

Note: The major products and services of each operating segment are as follows:

- Healthcare: Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
- Materials: Electronic materials, display materials, industrial equipment, fine chemicals, equipment and materials for graphic communication, inks and industrial inkjet printheads, etc.
- Business Innovation: Digital MFPs, solutions and services, etc.
- Imaging: Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

(B) Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended December 31, 2023 From October 1, 2023 To December 31, 2023		Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022		Change	
					Amount	%
Revenue:	%		%			
Domestic	32.6	250,130	32.8	244,186	5,944	2.4
Overseas:						
The Americas	22.4	171,874	24.5	182,724	(10,850)	(5.9)
Europe	17.5	133,931	15.9	118,372	15,559	13.1
Asia and others	27.5	211,006	26.8	199,047	11,959	6.0
Subtotal	67.4	516,811	67.2	500,143	16,668	3.3
Consolidated total	100.0	766,941	100.0	744,329	22,612	3.0

Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity

N/A

(Significant Subsequent Events)
(Stock Split and Partial Amendment of Articles of Incorporation)

The Company hereby announces that the Company has resolved at a meeting of its board of directors held on February 8, 2024 to implement a stock split and partially amend its Articles of Incorporation.

1. Purpose of stock split

The purpose is to reduce the minimum investment price through the stock split, thereby creating an environment where individual investors can more easily invest in the Company's shares and expanding the investor base.

2. Outline of stock split

(1) Method of stock split

Each share of common stock owned by shareholders listed or recorded in the closing register of shareholders on the record date of Sunday, March 31, 2024, will be split into three shares. Since this day falls on a non-business day of the shareholder registry administrator, the substantial record date will be Friday, March 29, 2024.

(2) Number of additional shares to be issued due to stock split

1.Total number of issued shares before the stock split	414,625,728 shares
2.Number of shares increased by the stock split	829,251,456 shares
3.Total number of issued shares following the stock split	1,243,877,184 shares
4.Total number of authorized shares following the stock split	2,400,000,000 shares

3. Schedule for stock split

Public notice of record date (scheduled): Monday, March 11, 2024
Record date: Sunday, March 31, 2024
Effective date: Monday, April 1, 2024

4. Impact on per share information

Per share information assuming that the stock split was performed at the beginning of the previous consolidated fiscal year is as follows.

	Nine months ended December 31, 2022 (From April 1, 2022 to December 31, 2022)	Nine months ended December 31, 2023 (From April 1, 2023 to December 31, 2023)
Net income attributable to FUJIFILM Holdings per share (yen)	127.81	144.36
Net income attributable to FUJIFILM Holdings per share (Assuming full dilution) (yen)	127.62	144.19

5. Partial amendment of Articles of Incorporation

(1) Reason for amendment

In connection with the stock split, a related provision of the Articles of Incorporation will be amended effective April 1, 2024, in accordance with Article 184, Paragraph 2 of the Companies Act.

(2) Details of amendment

The details of the amendment are as follows:

(Underlining indicates amendment)

Current Articles of Incorporation	Following the amendment
Chapter II: Shares	Chapter II: Shares
Article 6.	Article 6.
The total number of shares issuable by the Company is <u>800,000,000 shares.</u>	The total number of shares issuable by the Company is <u>2,400,000,000 shares.</u>

(3) Schedule for amendment

Date of Resolution of the Board of Directors: Thursday, February 8, 2024
Effective date: Monday, April 1, 2024

6. Other

(1) Change in the amount of stated capital

There will be no change in the amount of stated capital as a result of the stock split.

(2) Dividends

As the stock split will take effect on April 1, 2024, the year-end dividend for the fiscal year ending March 31, 2024, which has a dividend record date of March 31, 2024, will be paid based on the shares before the stock split.